On Thursday, Vertex Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 68 to 74. Please ...
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...
Investor's Business Daily on MSN3h
Stock Market Today: Chevron Breaks Out, But Biotechs Struggle As Eli Lilly Looks Like Short-Sale Play; Will American Airlines Break Out? (Live Coverage)Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...
From the end of November Market data will no longer be displayed here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback